Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
ADVM

ADVM - Adverum Biotechnologies Inc Stock Price, Fair Value and News

2.10USD+0.13 (+6.60%)Market Closed
Watchlist

Market Summary

USD2.10+0.13
Market Closed
6.60%

ADVM Alerts

  • 2 major insider buys recently.

ADVM Stock Price

View Fullscreen

ADVM RSI Chart

ADVM Valuation

Market Cap

212.2M

Price/Earnings (Trailing)

-1.68

Price/Sales (Trailing)

30.98

EV/EBITDA

-0.89

Price/Free Cashflow

-2.39

ADVM Price/Sales (Trailing)

ADVM Profitability

EBT Margin

-1681.51%

Return on Equity

-122.85%

Return on Assets

-64.13%

Free Cashflow Yield

-41.88%

ADVM Fundamentals

ADVM Revenue

Revenue (TTM)

7.5M

Rev. Growth (Yr)

-100%

Rev. Growth (Qtr)

-100%

ADVM Earnings

Earnings (TTM)

-126.2M

Earnings Growth (Yr)

18.06%

Earnings Growth (Qtr)

-4.36%

Breaking Down ADVM Revenue

Last 7 days

17.3%

Last 30 days

138.8%

Last 90 days

125.6%

Trailing 12 Months

223.0%

How does ADVM drawdown profile look like?

ADVM Financial Health

Current Ratio

4.32

ADVM Investor Care

Shares Dilution (1Y)

1.30%

Diluted EPS (TTM)

-1.26

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20230000
20220000
20210007.5M
20200000
20190000
20187.5M7.6M7.9M7.5M
20171.7M1.8M1.9M1.8M
20162.4M2.5M1.9M1.5M
2015745.0K813.0K1.6M2.3M
2014210.0K195.0K369.0K572.0K
2013142.5K255.0K367.5K480.0K
201200030.0K

Tracking the Latest Insider Buys and Sells of Adverum Biotechnologies Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 07, 2024
lupher, jr. mark l.
bought
175,500
1.35
130,000
-
Feb 07, 2024
scopa james paul
bought
135,000
1.35
100,000
-
Sep 15, 2023
seyedkazemi setareh
sold
-9,429
1.5206
-6,201
chief development officer
Jun 07, 2023
rubinstein linda m
bought
145,490
1.4549
100,000
chief financial officer
Mar 15, 2023
soparkar peter
sold
-10,442
0.7816
-13,360
chief operating officer
Mar 15, 2023
riley brigit
sold
-5,704
0.7816
-7,299
chief scientific officer
Mar 15, 2023
fischer laurent
sold
-32,232
0.7816
-41,239
ceo, president and director
Sep 19, 2022
beckman richard
sold
-4,569
1.0697
-4,272
chief medical officer
Sep 19, 2022
soparkar peter
sold
-14,232
1.0697
-13,305
see remarks section
Sep 19, 2022
seyedkazemi setareh
sold
-6,479
1.0696
-6,058
chief development officer

1–10 of 50

Which funds bought or sold ADVM recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 15, 2024
JANE STREET GROUP, LLC
sold off
-100
-50,816
-
-%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
reduced
-6.17
-391,031
348,019
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
358
83,398
147,451
-%
Feb 14, 2024
CAPTRUST FINANCIAL ADVISORS
sold off
-100
-30,750
-
-%
Feb 14, 2024
Newtyn Management, LLC
reduced
-19.7
-917,873
619,627
0.12%
Feb 14, 2024
Cubist Systematic Strategies, LLC
sold off
-100
-29,826
-
-%
Feb 14, 2024
VR Adviser, LLC
reduced
-21.69
-5,984,880
3,875,070
0.27%
Feb 14, 2024
Squarepoint Ops LLC
new
-
31,869
31,869
-%
Feb 14, 2024
NWAM LLC
unchanged
-
-7,472
7,528
-%
Feb 14, 2024
Soleus Capital Management, L.P.
new
-
319,940
319,940
0.04%

1–10 of 44

Are Funds Buying or Selling ADVM?

Are funds buying ADVM calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own ADVM
No. of Funds

Unveiling Adverum Biotechnologies Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 15, 2024
tcg crossover gp ii, llc
9.9%
20,763,572
SC 13G
Feb 14, 2024
vivo opportunity fund holdings, l.p.
7.2%
1.5e+07
SC 13G
Feb 14, 2024
commodore capital lp
9.9%
1e+07
SC 13G/A
Feb 14, 2024
venrock healthcare capital partners iii, l.p.
7.5%
15,564,213
SC 13G/A
Feb 13, 2024
bank of america corp /de/
4.4%
4,425,895
SC 13G/A
Feb 12, 2024
morgan stanley
5.1%
5,150,496
SC 13G/A
Feb 09, 2024
frazier life sciences public fund, l.p.
2.4%
5,003,125
SC 13G
Feb 09, 2024
fmr llc
-
0
SC 13G/A
Feb 07, 2024
bml investment partners, l.p.
2.2%
4,554,252
SC 13G/A
Jul 24, 2023
venrock healthcare capital partners iii, l.p.
5.9%
5,899,489
SC 13G

Recent SEC filings of Adverum Biotechnologies Inc

View All Filings
Date Filed Form Type Document
Feb 22, 2024
SC 13G
Major Ownership Report
Feb 21, 2024
D
D
Feb 15, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
4
Insider Trading
Feb 14, 2024
4
Insider Trading
Feb 14, 2024
4
Insider Trading
Feb 14, 2024
4
Insider Trading
Feb 14, 2024
SC 13G
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report
Feb 14, 2024
SC 13G/A
Major Ownership Report

Peers (Alternatives to Adverum Biotechnologies Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
37.9B
9.1B
-16.59% -47.80%
-10.94
4.16
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
20.5B
1.8B
-23.99% -31.71%
-46.58
11.22
76.23% 61.08%
16.9B
2.3B
-4.89% -18.90%
115.27
7.33
15.05% 75.21%
13.7B
3.7B
-7.62% -26.87%
22.88
3.7
8.87% 75.42%
MID-CAP
8.0B
272.9M
-2.06% 34.31%
-13.22
29.35
141.38% 4.43%
6.5B
-
-3.85% 226.12%
-10.45
60.35
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.42
6.46
23.54% 31.53%
3.8B
223.4M
8.92% 47.81%
-18.87
17.04
-35.86% -26.24%
3.7B
240.7M
-19.08% -10.99%
-12.61
15.54
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.89
4.25
81.69% -7.29%
579.7M
1.0B
-9.17% -57.89%
-1.06
0.55
-43.15% 58.48%
174.3M
4.9M
-14.18% -58.18%
-1.06
35.65
-57.57% 50.48%
112.6M
881.7K
289.54% 381.25%
-2.37
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Adverum Biotechnologies Inc News

Latest updates
InvestorsObserver18 hours ago
InvestorsObserver09 Feb 202408:00 am
Yahoo Finance04 Jan 202408:00 am

Adverum Biotechnologies Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q4
Revenue---3,600,0002,880,0002,160,0001,440,000720,000---7,500,0006,464,2865,428,5714,392,8573,357,1432,321,4291,285,714250,000190,000130,00070,000
Operating Expenses4.4%34,529,00033,065,00033,839,00033,940,00041,037,00044,025,00038,133,00034,419,00038,522,00044,538,00036,143,000-36,380,00028,004,00029,775,00023,791,00019,653,00017,333,00016,102,00015,707,00016,829,000
  S&GA Expenses10.6%13,789,00012,466,00012,780,00011,741,00017,188,00013,760,00015,169,00011,895,00014,453,00021,930,00016,163,000-13,652,00011,351,00010,598,0009,040,0008,279,0007,389,0007,132,0005,576,0005,187,000
  R&D Expenses0.7%20,740,00020,599,00021,059,00022,199,00023,849,00030,265,00022,964,00022,524,00024,069,00022,608,00019,980,000-22,728,00016,653,00019,177,00014,751,00011,374,0009,944,0008,970,00010,131,00011,642,000
EBITDA Margin5.5%-15.97-16.90-18.52-19.72-20.00-19.88-20.01-18.78-14.85-14.82-14.80-14.88-14.88--------
Income Taxes-19.0%17,00021,00017,00019,00017,00019,00019,000--------------
Earnings Before Taxes-4.4%-32,868,000-31,489,000-29,039,000-32,717,000-40,114,000-43,742,000-37,889,000-34,409,000-38,362,000-44,333,000-28,436,000------18,925,000-16,118,000---15,659,000
EBT Margin5.4%-16.82-17.78-19.41-20.59-20.82-20.59-20.67-19.41-15.43-15.43-15.43-15.43-15.43--------
Net Income-4.4%-32,885,000-31,510,000-29,056,000-32,736,000-40,131,000-43,761,000-37,908,000-34,409,000-38,362,000-44,333,000-28,436,000--37,632,000-27,769,000-29,200,000-22,906,000-18,925,000-16,118,000-14,954,000-14,489,000-15,659,000
Net Income Margin5.4%-16.82-17.79-19.42-20.60-20.83-20.59-20.67-19.41-19.72-18.32-16.31-15.58-15.58--------
Free Cashflow-4.8%-24,408,000-23,285,000-22,497,000-18,660,000-32,632,000-35,312,000-33,303,000-30,167,000-31,515,000-37,563,000-23,709,000-23,657,000-23,657,000--------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-18.5%197241276308332375407440491526462483508331349223206210221213226
  Current Assets-15.3%125147169191213246280317348386410434460283300176168181193209222
    Cash Equivalents-5.2%10511168.0068.0084.0092.0090.0037.0033.0047.0045.0063.0073.0027.0013067.0074.0099.00145156160
  Net PPE-51.6%15.0032.0033.0035.0037.0038.0037.0033.0037.0032.0028.0028.0027.0027.0027.0025.0015.006.004.004.003.00
Liabilities-14.7%94.0011011812712413112412414514747.0048.0043.0049.0045.0048.0041.0032.0033.0012.0010.00
  Current Liabilities-35.2%29.0045.0046.0032.0029.0031.0023.0021.0025.0021.0020.0021.0016.0021.0017.0019.0018.0010.0011.0011.0010.00
Shareholder's Equity-21.7%103131158182208244283316346379415434465283304175164178188201216
  Retained Earnings-3.8%-896-863-831-802-769-729-685-648-613-575-531-502-464-437-407-385-366-349-335-320-304
  Additional Paid-In Capital0.4%999995990986980976970965960955946937930720713561531528524523521
Shares Outstanding0.2%10110110010099.0099.0099.0098.0098.0098.0098.0098.0081.00--------
Float------115---320---1,500---675---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-2.9%-23,913-23,249-22,412-18,475-31,808-28,879-28,929-25,815-25,796-33,915-22,305-22,224-26,544-16,907-13,616-14,835-9,530-11,588-13,217-12,730-16,900
  Share Based Compensation-1.8%4,3894,4694,5635,2534,5034,9425,3814,4105,3268,2347,2246,1776,0204,7853,4092,8502,6612,6261,7621,1822,995
Cashflow From Investing-72.8%18,19767,02321,5332,23424,36830,73584,38323,88310,47037,7776,57911,576-132,373-88,627-70,743-19,210-15,016-36,5922,7458,02721,138
Cashflow From Financing-1412.5%-1058.00-242-3623.00375-5171,505376204,2542,731148,62426,771-91.001,881-370-21.00-15.00

ADVM Income Statement

2023-09-30
Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)
shares in Thousands, $ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Income Statement [Abstract]    
License revenue$ 0$ 0$ 3,600$ 0
Operating expenses:    
Research and development20,74023,84962,39877,078
General and administrative13,78917,18839,03546,117
Total operating expenses34,52941,037101,433123,195
Operating loss(34,529)(41,037)(97,833)(123,195)
Other income, net1,6619234,4371,450
Net loss before income taxes(32,868)(40,114)(93,396)(121,745)
Income tax provision(17)(17)(55)(55)
Net loss(32,885)(40,131)(93,451)(121,800)
Other comprehensive income (loss):    
Net unrealized gain/(loss) on marketable securities66(127)1,003(1,189)
Foreign currency translation adjustment(12)(30)(24)(50)
Comprehensive loss$ (32,831)$ (40,288)$ (92,472)$ (123,039)
Net loss per share — basic (in USD per share)$ (0.33)$ (0.40)$ (0.93)$ (1.23)
Net loss per share — diluted (in USD per share)$ (0.33)$ (0.40)$ (0.93)$ (1.23)
Weighted-average common shares used to compute net loss per share - basic (in shares)100,99999,475100,69399,027
Weighted-average common shares used to compute net loss per share - diluted (in shares)100,99999,475100,69399,027

ADVM Balance Sheet

2023-09-30
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 105,366$ 68,431
Short-term investments11,716117,158
Prepaid expenses and other current assets7,5145,006
Total current assets124,596190,595
Operating lease right-of-use assets52,75778,934
Property and equipment, net15,49734,927
Restricted cash2,6502,503
Deposit and other long-term assets1,2701,413
Total assets196,770308,372
Current liabilities:  
Accounts payable2,1702,238
Accrued expenses and other current liabilities16,36216,767
Lease liability, current portion10,32413,241
Total current liabilities28,85632,246
Lease liability, net of current portion65,20093,561
Other non-current liabilities01,047
Total liabilities94,056126,854
Stockholders’ equity:  
Preferred stock00
Common stock1010
Additional paid-in capital999,319985,651
Accumulated other comprehensive loss(552)(1,531)
Accumulated deficit(896,063)(802,612)
Total stockholders’ equity102,714181,518
Total liabilities and stockholders’ equity$ 196,770$ 308,372
ADVM
Adverum Biotechnologies, Inc., a clinical-stage company, develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ixoberogene soroparvovec (ADVM-022), a single intravitreal injection gene therapy candidate used for the treatment of patients with chronic retinal, including wet age-related macular degeneration and diabetic macular edema. The company is developing ADVM-062 (AAV.7m8-L-opsin), a novel gene therapy product candidate for the treatment of blue cone monochromacy via a single IVT injection. Adverum Biotechnologies, Inc. has license and collaboration agreements with University of California; GenSight Biologics; Lexeo Therapeutics; and Virovek, Inc. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was incorporated in 2006 and is headquartered in Redwood City, California.
 CEO
 WEBSITEadverum.com
 EMPLOYEES123

Adverum Biotechnologies Inc Frequently Asked Questions


What is the ticker symbol for Adverum Biotechnologies Inc? What does ADVM stand for in stocks?

ADVM is the stock ticker symbol of Adverum Biotechnologies Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Adverum Biotechnologies Inc (ADVM)?

As of Thu Feb 22 2024, market cap of Adverum Biotechnologies Inc is 212.16 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of ADVM stock?

You can check ADVM's fair value in chart for subscribers.

What is the fair value of ADVM stock?

You can check ADVM's fair value in chart for subscribers. The fair value of Adverum Biotechnologies Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Adverum Biotechnologies Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for ADVM so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Adverum Biotechnologies Inc a good stock to buy?

The fair value guage provides a quick view whether ADVM is over valued or under valued. Whether Adverum Biotechnologies Inc is cheap or expensive depends on the assumptions which impact Adverum Biotechnologies Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ADVM.

What is Adverum Biotechnologies Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Feb 22 2024, ADVM's PE ratio (Price to Earnings) is -1.68 and Price to Sales (PS) ratio is 30.98. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ADVM PE ratio will change depending on the future growth rate expectations of investors.